Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599946 | 0.91 | BMP1 (0.80) | BMP1MMP2 | |
| SCHEMBL6598160 | 0.90 | BMP1 (0.62) | BMP1MMP2 | |
| SCHEMBL6598264 | 0.88 | BMP1 (0.83) | BMP1MMP2 | |
| SCHEMBL6595627 | 0.88 | BMP1 (0.72) | BMP1MMP2 | |
| SCHEMBL6597336 | 0.88 | BMP1 (0.82) | BMP1MMP2 | |
| SCHEMBL6596012 | 0.87 | BMP1 (0.72) | BMP1 | |
| SCHEMBL6599533 | 0.87 | BMP1 (0.69) | BMP1 | |
| SCHEMBL6595914 | 0.84 | BMP1 (0.69) | BMP1MMP2 | |
| SCHEMBL6598984 | 0.83 | BMP1 (0.68) | BMP1MMP2 | |
| SCHEMBL6602117 | 0.82 | BMP1 (0.75) | BMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-6821972-B2 | ANTISCARRING AGENTS; WOUND HEALING AGENTS; ENZYME INHIBITORS | PFIZER INC. | 2004-11-23 | — | — | US | disclosed |
| EP-1373264-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PFIZER INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069291-A1 | 3-heterocyclylpropanohydroxamic acid PCP inhibitors | PAH, CYP2F1, CYP7A1 | BMP1 449/4885MMP2 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.